Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations
Launched by UCB PHARMA · Apr 19, 2011
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with a diagnosis of idiopathic Parkinson´s disease, and continuous treatment with commercially available rotigotine transdermal patch for at least 3 months, and a stable rotigotine dose including an 8 mg/24 h patch for at least 2 weeks prior to enrollment
- Exclusion Criteria:
- • Subjects has previously participated in this study, failed to be screened, or has participated in another study with an investigational medicinal product (IMP) or medical device within the last 30 days or is currently participating in such
- • Subject with a history of significant skin hypersensitivity to adhesives, other transdermal products or recently unsolved contact dermatitis
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Innsbruck, , Austria
Wien, , Austria
Stuttgart, , Germany
Newcastle Upon Tyne, , United Kingdom
Liverpool, , United Kingdom
Blackpool, , United Kingdom
Bochum, , Germany
Norwich, , United Kingdom
Koln, , Germany
Karlstadt, , Germany
Norwich, , United Kingdom
Gera, , Germany
Derby, , United Kingdom
Berlin, , Germany
Alzenau, , Germany
Boblingen, , Germany
Wolfach, , Germany
Patients applied
Trial Officials
UCB Clinical Trial Call Center
Study Director
+1 877 822 9493 (UCB)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials